Publications by authors named "Emma de Brabander"
Background: Research on the pharmacogenetic influence of hepatic enzyme 2D6 () on metabolism of drugs for psychosis and associated outcome has been inconclusive. Some results suggest increased risk of adverse reactions in poor and intermediate metabolizers, while others find no relationship. However, retrospective designs may fail to account for the long-term pharmacological treatment of patients.
View Article and Find Full Text PDFBackground: Pharmacogenetics is considered a promising avenue for improving treatment outcomes, yet evidence arguing for the use of pharmacogenetics in the treatment of psychotic disorders is mixed and clinical usefulness is under debate. Many patients with psychosis use multiple medications, which can alter the metabolic capacity of enzymes, a process called phenoconversion. In clinical studies, treatment outcomes of drugs for psychosis management may have been influenced by phenoconversion.
View Article and Find Full Text PDFArticle Synopsis
- Variability in cytochrome P450 enzymes (CYP2C19 and CYP2D6) may affect the side effects and effectiveness of commonly used antipsychotics like aripiprazole and risperidone, which are primarily metabolized by CYP2D6.
- A systematic review analyzed 2007 publications, ultimately including 34 studies, and evaluated their quality using specific assessment tools, revealing concerns such as high risk of bias in most randomized controlled trials (RCTs).
- The majority of studies focused on CYP2D6 without strong evidence linking it to side effects, while only one study found a positive relation of CYP2C19 with neurological side effects from risperidone; thus, more